Liposomes in Cancer Therapy: How Did We Start and Where Are We Now

Area of Science:

• Nanotechnology
• Oncology
• Pharmaceutics

Background:

• Liposomes, discovered in the 1960s, are widely recognized as effective nanocarriers for cancer drug delivery.
• Numerous liposomal formulations have gained regulatory approval (FDA, EMA) and are progressing through clinical trials.
• Key advantages include enhanced drug pharmacokinetics, reduced systemic toxicity, prolonged circulation, and tumor site accumulation via the EPR effect.

Purpose of the Study:

• To review the fundamental properties of liposomes as drug delivery systems.
• To summarize the current clinical applications of liposomes in cancer therapy.
• To identify the limitations and challenges hindering maximal therapeutic efficacy and clinical translation.

Main Methods:

• Literature review of liposome properties and applications in cancer therapy.
• Analysis of approved and investigational liposomal drug formulations.
• Evaluation of the enhanced permeability and retention (EPR) mechanism in tumor targeting.
• Discussion of liposome-induced toxicity and targeting specificity issues.

Main Results:

• Liposomes demonstrate significant potential in improving cancer treatment outcomes.
• Approved liposomal drugs highlight their clinical viability and therapeutic benefits.
• The EPR effect contributes to passive tumor targeting, but limitations in specificity exist.
• Potential toxicities and challenges in achieving precise targeting remain significant hurdles.

Conclusions:

• Liposomes offer substantial benefits for cancer drug delivery, including improved pharmacokinetics and reduced toxicity.
• Despite successes, challenges related to specific targeting and potential toxicity require further investigation.
• Addressing these limitations is crucial for advancing liposome-based cancer therapies and maximizing their clinical impact.